The same Department of Defense agency best known for developing stealth airplanes, laser-guided bombs, and the Internet, is now turning its attention to synthetic biology.

That’s right, the Defense Advanced Research Projects Agency — better known as DARPA — is carving out a significant portion of its $2.9 billion dollar budget to focus on genetically engineered bacteria, bionic limbs, and synthetic vaccines.

These initiatives will run through its Biological Technologies Office — their latest branch, whose operation was announced just this Thursday after spending a year in development.

With more than $300 million in funding, DARPA believes the new office will solve some of the greatest problems facing the military today — from more rapidly stabilizing battlefield injuries, to protecting troops supporting virus outbreaks such as Ebola.

This comes at a critical time when advances in precision medicine are just becoming affordable. A decade ago, it took two months to have your genome sequenced, at extraordinary cost. Today, we can map a single human genome in an hour — for just under $1,000.

Unfortunately, you can’t have new technology without critics!

A group of prominent scientists are calling for a temporary halt on the genetic editing of human DNA, published in the journal Nature. They’re calling for stronger policies at the national level that would protect the alteration of the DNA of human sperm, eggs, and embryos.

Then there’s Elon Musk, the founder and father of innovation at Tesla Motors and Space-X. Back in January, he announced he was donating $10 million dollars to “keep artificial intelligence from turning evil.” Considering the way AI and biotech have essentially merged into one force in recent years, that comes as a hit.

But make no mistake, we now have and are leveraging new technology to forge a new frontier in medicine and health. As with all things, there will be some bumps and bruises — hence the critical onslaught — but we’re getting there at rapid speed.

If biotech is something you’re interested in, and you want to avoid some of those bumps and bruises facing the wider technology sector, then check out my service: BioTech Intel Trader.

Image Signature


Your Special Boom & Bust Offer!

Investing is no longer a set-it-and-forget-it affair. If you’re still using that outdated approach in today’s irrational markets, you’re setting yourself up for massive losses and a difficult retirement. There’s a much… Read More>>
Ben Benoy
Ben Benoy is a veteran of the U.S. Marine Corps and has been an active retail trader since 2006. He identifies investment opportunities based on key social media trends. He first identified the concept in 2008 and has since developed a tool for tracking investment “chatter” between social media users. His proprietary Social Media Stock Sentiment system has developed into a state-of-the-art platform that identifies and classifies chatter about stocks through algorithms and other indicators to forecast stock-price direction. Ben’s track record speaks for itself — over the past 12 months, his system boasts a win rate of 82.2% on 112 stock trades.